Welcome to our dedicated page for Axsome Therapeut SEC filings (Ticker: AXSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Axsome Therapeutics, Inc. (NASDAQ: AXSM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a biopharmaceutical issuer focused on central nervous system (CNS) conditions, Axsome uses its SEC reports to communicate financial results, product revenue for AUVELITY, SUNOSI, and SYMBRAVO, and updates on its development pipeline, which includes programs such as AXS-05, AXS-12, AXS-14, solriamfetol in new indications, and AZD7325.
Among the filings, Form 8-K current reports are especially relevant for tracking material events. For example, Axsome has filed 8-Ks to furnish press releases announcing quarterly financial results and to disclose updates such as the receipt of a Paragraph IV Certification Notice Letter regarding a proposed generic version of SYMBRAVO. These documents help investors understand how clinical progress, intellectual property developments, and commercial performance affect the company.
In addition to 8-Ks, investors typically review Axsome’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain detailed discussions of net product revenue, research and development spending, selling and administrative expenses, risk factors, and descriptions of the company’s CNS portfolio and pipeline. Proxy statements and, when applicable, Forms 3, 4, and 5 can provide information on insider holdings and transactions, while registration statements and prospectuses outline capital-raising activities.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents such as 10-Ks, 10-Qs, and major 8-Ks in plain language. Real-time EDGAR updates help ensure that new Axsome filings appear promptly, and AI-generated highlights can make it easier to locate information on topics such as AXS-05’s regulatory status, AXS-12’s Orphan Drug Designation, or revenue trends for AUVELITY, SUNOSI, and SYMBRAVO without reading every page of the underlying filing.
Axsome Therapeutics, Inc. Chief Operating Officer Mark L. Jacobson reported an exercise-and-sell transaction in company stock. He exercised stock options to acquire 4,750 shares of common stock at $12.95 per share, then sold the same 4,750 shares in open-market transactions at weighted average prices of about $227.94 and $228.18.
The footnotes state these options had been held for 7 years and were exercised before their 10-year expiration, and that the sales were made under a pre-approved Rule 10b5-1 plan, which has now been completed. Following the sales, he reports no directly held common shares but continues to hold 114,954 stock options expiring on March 19, 2029.
The filing is a Rule 144 notice reporting proposed sales of Class A Common shares by Mark Jacobson and related entries. The excerpt lists three recent dispositions: 15,378 shares on 02/26/2026 for $2,505,062.36, 20,000 shares on 02/26/2026 for $3,221,848, and 4,517 shares on 05/04/2026 for $1,029,598.66. The filing notes securities were acquired as compensation and a cashless exercise / same-day sale method is referenced.
Axsome Therapeutics insider transaction disclosure: The filing notifies a proposed sale of Class A Common shares tied to a cashless exercise / same-day sale following a stock option acquisition on 05/04/2026. The filing also lists two prior sales by Mark Jacobson on 02/26/2026 of 15,378 shares for $2,505,062.36 and 20,000 shares for $3,221,848. The planned method is described as a cashless exercise with same-day sale; timing and exact number of shares proposed for sale on 05/04/2026 are not specified in this excerpt.
Axsome Therapeutics reports insider Form 144 notice for sales of Class A Common stock by Mark Jacobson. The filing lists securities to be sold on 05/04/2026 described as "Acquired as compensation -- Stock Options" with planned cashless exercise / same-day sale treatment. The excerpt also records completed sales on 02/26/2026 of 15,378 and 20,000 shares.
Axsome Therapeutics reported first‑quarter 2026 results, showing rapid top‑line growth but continued losses as it invests in commercialization and pipeline expansion.
Total revenue reached $191.2 million, up from $121.5 million a year earlier, driven mainly by product sales of $189.4 million. Net loss widened modestly to $64.5 million, or $1.26 per share, as selling, general and administrative expenses increased to support AUVELITY, SUNOSI, and SYMBRAVO.
Cash and cash equivalents were $305.1 million at March 31, 2026, and operating activities used $20.7 million of cash, an improvement versus the prior‑year period. Total assets were $713.6 million and stockholders’ equity declined to $54.6 million, reflecting the cumulative deficit of $1.37 billion. The company believes its existing cash will fund operations for at least twelve months while it scales three commercial CNS products and advances new assets such as AXS‑17 and AXS‑20.
Axsome Therapeutics reported first-quarter 2026 results with total net product revenue of $191.2M, up 57% year over year. Growth was led by AUVELITY, which generated $153.2M in net product revenue, a 59% increase, while SUNOSI contributed $33.9M and SYMBRAVO $4.1M.
Total operating expenses rose as Axsome expanded commercial efforts and R&D, including pre-launch spending for AUVELITY’s new indication and pipeline development. The company posted a net loss of $64.5M, or $1.26 per share, and ended March 31, 2026 with cash and cash equivalents of $305.1M.
AUVELITY received U.S. FDA approval for agitation associated with dementia due to Alzheimer’s disease, with a U.S. commercial launch planned for June 2026. Axsome also highlighted a broad late-stage neuroscience pipeline, including an NDA submission for AXS-12 in narcolepsy and multiple Phase 3 programs for solriamfetol.
Axsome Therapeutics announced that the U.S. Food and Drug Administration approved AUVELITY (dextromethorphan HBr/bupropion HCl) for the treatment of agitation associated with dementia due to Alzheimer’s disease. This makes Auvelity a first-in-class oral therapy for this indication, targeting NMDA and sigma‑1 receptors.
The approval follows Phase 3 ADVANCE-1 and ACCORD-2 trials, where Auvelity showed statistically significant improvement in agitation symptoms versus placebo and a longer time to relapse in responders. Agitation affects up to 76% of Alzheimer’s patients in a population of more than 7 million Americans, highlighting the clinical need addressed by this new indication.
Axsome Therapeutics is asking stockholders to vote at its 2026 Annual Meeting, a fully virtual event scheduled for June 5, 2026 at 9:00 a.m. EDT. Holders of common stock at the close of business on April 14, 2026, when 51,439,952 shares were outstanding, may attend online, submit questions, and vote.
Stockholders will elect two Class II directors to terms ending in 2029, ratify Deloitte & Touche LLP as independent auditor for 2026, and cast a non-binding advisory vote on named executive officer compensation. The board unanimously recommends voting “FOR” all three proposals. The proxy statement also details board composition, diversity data, executive and director pay, committee structures, and Axsome’s ESG and governance practices.
Jacobson Mark L. reported acquisition or exercise transactions in this Form 4 filing.
Axsome Therapeutics, Inc. reported that Chief Operating Officer Mark L. Jacobson received a grant of 8,669 Performance Stock Units (PSUs). Each PSU represents a contingent right to receive one share of Axsome common stock.
The PSUs will vest only if specified sales and commercial launch milestones are achieved and if Jacobson remains in service through each vesting date. Following this grant, he holds 8,669 PSUs directly as part of his equity-based compensation.